BOKF NA trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 95.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 664 shares of the company's stock after selling 15,125 shares during the period. BOKF NA's holdings in Moderna were worth $28,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of MRNA. Principal Financial Group Inc. lifted its stake in Moderna by 4.2% during the third quarter. Principal Financial Group Inc. now owns 379,451 shares of the company's stock valued at $25,359,000 after purchasing an additional 15,218 shares during the last quarter. Czech National Bank increased its holdings in shares of Moderna by 6.6% in the fourth quarter. Czech National Bank now owns 73,424 shares of the company's stock valued at $3,053,000 after buying an additional 4,526 shares in the last quarter. Green Alpha Advisors LLC lifted its position in shares of Moderna by 54.9% during the 4th quarter. Green Alpha Advisors LLC now owns 16,900 shares of the company's stock valued at $703,000 after acquiring an additional 5,987 shares during the last quarter. 180 Wealth Advisors LLC lifted its position in shares of Moderna by 3.2% during the 4th quarter. 180 Wealth Advisors LLC now owns 18,557 shares of the company's stock valued at $772,000 after acquiring an additional 578 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Moderna by 13.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 14,978 shares of the company's stock worth $623,000 after acquiring an additional 1,819 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.
Moderna Price Performance
Shares of MRNA traded down $0.37 during trading hours on Thursday, hitting $23.65. The stock had a trading volume of 14,856,180 shares, compared to its average volume of 7,694,092. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The stock has a market capitalization of $9.15 billion, a price-to-earnings ratio of -2.55 and a beta of 1.99. The company's fifty day moving average is $28.52 and its two-hundred day moving average is $36.08.
Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. The business had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna's revenue for the quarter was down 35.3% on a year-over-year basis. During the same period in the prior year, the company earned ($3.07) EPS. Equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
MRNA has been the topic of a number of recent analyst reports. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research report on Thursday, April 17th. Evercore ISI reduced their price objective on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. UBS Group decreased their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Citigroup initiated coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Finally, Leerink Partners decreased their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average target price of $53.95.
View Our Latest Analysis on MRNA
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
